Last reviewed · How we verify
NCT05630989
A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
trial testing combination therapy with no MEKi in Pancreatic Ductal Adenocarcinoma in 80 participants. Currently enrolling.
1 August 2027
Quick facts
| Lead sponsor | Mandana Kamgar, MD |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 7 February 2023 |
| Primary completion | 1 August 2027 |
| Estimated completion | 1 August 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- combination therapy with no MEKi
- combination therapy with MEKi-HCQ — full drug profile →
- combination therapy with MEKi-EGFRi — full drug profile →
- combination therapy with MEKi. — full drug profile →
Conditions studied
- Pancreatic Ductal Adenocarcinoma — all drugs for Pancreatic Ductal Adenocarcinoma →
Sponsor
Mandana Kamgar, MD — full company profile →
Who can join
18 and older, any sex, with Pancreatic Ductal Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an observational precision oncology study designed to collect and analyze data that allows us to characterize the safety and efficacy of several different mitogen-activated protein kinase kinase inhibitor (MEKi) -based treatment strategies and the feasibility of administering MEKi combination therapies to patients with KRAS G12R mutated advanced pancreatic ductal adenocarcinoma (PDAC).
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Genetics and biology of pancreatic ductal adenocarcinoma.
Ying H, Kimmelman AC, Bardeesy N, Kalluri R, et al · · 2025 · cited 20× · PMID 39510840 · DOI 10.1101/gad.351863.124 -
Kinome state is predictive of cell viability in pancreatic cancer tumor and cancer-associated fibroblast cell lines.
Berginski ME, Jenner MR, Joisa CU, Herrera Loeza G, et al · · 2024 · cited 3× · PMID 39221276 · DOI 10.7717/peerj.17797 -
Decoding Drug Resistance in Pancreatic Cancer: A Subcellular Structure Perspective.
Li X, Lyu H, Wu Y, Chen A, et al · · 2026 · PMID 41972577 · DOI 10.3390/biology15070574 -
Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma.
Kamgar M, Hobbes GA, Davidson R, Dorbin D, et al · · 2026 · PMID 41134578 · DOI 10.1158/0008-5472.can-25-0018
Verify or expand the search:
- PubMed search for NCT05630989
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatic Ductal Adenocarcinoma
Currently open trials in the same condition.
- NCT07324096 — A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Deve · NA · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07328607 — Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy · NA · recruiting
- NCT07232810 — Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer · NA · recruiting
- NCT07261631 — Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05630989 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mandana Kamgar, MD
- Last refreshed: 24 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05630989.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing